Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

2.3K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
2.3K
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

905
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
905
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

1.2K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.2K
Dialysis01:27

Dialysis

1.7K
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
1.7K
Dialysis01:15

Dialysis

2.0K
Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
2.0K
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

654
Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
654

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factor obesity: Treatment Standard.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

PREVENT Equations: Implications for Stroke Prevention.

Stroke·2026
Same author

Differences in the Prevalence of Recurrent Urinary Tract Infections in Women Based on Dietary Habits.

Urology·2026
Same author

FLOWing Toward Holistic Care: Heart-Kidney-Metabolic Health Re-Imagined.

Journal of the American College of Cardiology·2026
Same author

Cardiovascular Kidney Metabolic Health: Historical Perspective and Opportunities for Nephrology.

Kidney360·2026
Same author

A Scoping Review of Pharmacist-Based Interprofessional Interventions for Management of Cardiovascular-Kidney-Metabolic Conditions.

Journal of the American College of Clinical Pharmacy : JACCP·2026

Related Experiment Video

Updated: Feb 27, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.9K

Subcutaneous defibrillators for dialysis patients.

Tushar J Vachharajani1, Loay Salman2, Eric J Costanzo3

  • 1Division of Nephrology, W.G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina.

Hemodialysis International. International Symposium on Home Hemodialysis
|June 24, 2017
PubMed
Summary

Subcutaneous implantable cardioverter defibrillators (ICDs) offer lead-free defibrillation, avoiding complications like central venous stenosis and tricuspid regurgitation common with traditional ICDs. This makes them a promising option for hemodialysis patients.

Keywords:
Subcutaneous defibrillatordialysis catheterhemodialysis

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

Related Experiment Videos

Last Updated: Feb 27, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.9K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

Area of Science:

  • Cardiology
  • Medical Devices
  • Nephrology

Background:

  • Traditional implantable cardioverter defibrillators (ICDs) utilize leads that pose risks such as central venous stenosis, lead-induced endocarditis, and tricuspid regurgitation.
  • These lead-related complications are particularly concerning for hemodialysis patients due to pre-existing vascular and cardiac considerations.
  • Central venous stenosis, infection, and tricuspid regurgitation are critical issues impacting the health and treatment of patients requiring long-term hemodialysis.

Purpose of the Study:

  • To highlight the risks associated with transvenous leads in traditional implantable cardioverter defibrillators.
  • To raise awareness of the benefits and potential of subcutaneous implantable cardioverter defibrillators (ICDs) for hemodialysis patients.
  • To discuss the suitability of leadless ICDs in the context of hemodialysis and its associated complications.

Main Methods:

  • Review of existing literature and clinical reports concerning traditional ICD lead complications.
  • Analysis of the advantages of subcutaneous ICDs in circumventing lead-related issues.
  • Discussion of recent findings supporting subcutaneous ICD use in renal patients undergoing hemodialysis.

Main Results:

  • Subcutaneous ICDs provide successful defibrillation without the need for transvenous leads.
  • Elimination of leads significantly reduces the risk of central venous stenosis, endocarditis, and tricuspid valve complications.
  • Emerging evidence suggests subcutaneous ICDs are a viable and beneficial option for hemodialysis patients.

Conclusions:

  • Subcutaneous ICDs offer a safer alternative to traditional ICDs for patients, especially those on hemodialysis.
  • The lead-free nature of subcutaneous ICDs mitigates serious complications relevant to the hemodialysis population.
  • Further adoption of subcutaneous ICDs is recommended to improve patient outcomes in this vulnerable group.